4 results about "Erythrocyte lysis" patented technology

This invention belongs to the field of biomedical technology and provides a high-throughput drug screening system and its usage method for enriching circulating tumor cells (CTCs) in liver cancer. It includes an information processing and control unit; a diseased liver perfusion device comprising an organ chamber containing injection fluid at the bottom, an arterial supply line, an arterial end sensor, an arterial end clamp valve, at least two membrane lungs, a portal vein supply line, a portal vein end clamp valve, and a portal vein end sensor; a CTC enrichment device, which uses erythrocyte lysis to remove erythrocytes and immunomagnetic bead labeling to remove leukocytes, enabling the processing of large volumes of perfusion fluid in a single step to obtain enriched circulating tumor cells; a high-throughput drug screen; and phototubes, arterial end sensors, and portal vein end sensors, each electrically connected to the information processing and control unit. Compared with existing technologies, the high-throughput drug screening system and its usage method of this invention have the advantages of establishing a room-temperature mechanically perfused ex vivo liver cancer model, realizing the processing of large volumes of liquid specimens, and providing automated high-throughput drug screening functionality.

The application discloses a method for detecting circulating tumor cells based on cell membrane surface sialic acid expression quantity and single cell detection technology, and belongs to the field of biomedical technology. The method comprises the following steps: using a boron acid group modified probe to label cell surface sialic acid in a blood sample after erythrocyte lysis; passing the labeled sample through a phase transfer flow focusing chip to enrich and purify circulating tumor cells based on cell size; and detecting the enriched and purified cells by a single cell analysis method. The application solves the problems of high cost, long time consumption and high missed detection rate of the current circulating tumor cell detection method applied in clinical practice, and provides a method with simple operation and higher universality for circulating tumor cell detection.

This invention belongs to the fields of biotechnology and precision oncology, and discloses a serum-free amplification method for circulating tumor cells (CTCs) based on apoptosis selectivity, along with a dedicated culture medium. This addresses the problems of existing CTC technologies, which rely on physical capture leading to impaired cell viability and low culture success rates. The invention involves mild density gradient centrifugation and erythrocyte lysis of anticoagulated whole blood from patients to obtain a mixed population of leukocytes containing CTCs. This population is then seeded into a serum-free, selective apoptosis medium for three-dimensional culture. The medium contains apoptosis inhibitors and specific growth factors. Utilizing the difference between tumor cells' anti-apoptosis and normal blood cells' susceptibility to apoptosis, leukocyte apoptosis is induced within 4-7 days, while simultaneously supporting CTC survival, adhesion, and clonal proliferation, enabling the amplification of individual CTCs into cell clusters. This method preserves the original activity and heterogeneity of CTCs, is simple to operate, and has good reproducibility, providing a highly active cell source for CTC molecular identification, drug sensitivity testing, and metastasis mechanism research.

This invention belongs to the field of biomedical technology, specifically relating to a method and kit for improving the sensitivity and specificity of circulating tumor cell (CTC) detection. The method first treats anticoagulated blood with erythrocyte lysis buffer, centrifuges to obtain a cell suspension (including leukocytes and circulating tumor cells); then, a radiosensitizer is added and the suspension is irradiated; next, single-cell gel electrophoresis is used to detect the degree of DNA damage in the test cells; finally, leukocytes and tumor cells are distinguished based on cell morphology using a fluorescence microscope or fluorescence scanner. This invention is the first to detect the number and type of circulating tumor cells (CTCs) in peripheral blood based on ionizing radiation and radiosensitization effects, according to the degree of DNA damage in tumor cells. Compared with existing technologies, this detection method and kit are not only simple and rapid, but also significantly improve detection sensitivity and specificity. Furthermore, it is independent of the physical properties of cells and tumor cell surface markers, requires a small sample volume, is highly versatile, and can detect CTCs in different types of solid tumors.